MASHINIi

CytoMed Therapeutics Limited.

GDTC.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products

CytoMed Therapeutics Limited, a Singapore-based biotechnology company, focuses on the research, development, and commercialization of novel immunotherapies for the treatment of cancers. The company's lead product candidate is CTM-GDT1, an allogeneic gamma delta T cell therapy for the treatment of so...Show More

Ethical Profile

Mixed.

CytoMed Therapeutics Limited presents a mixed ethical profile. While the pre-clinical biopharmaceutical company is dedicated to "Better Health for All" through developing cell-based immunotherapies for cancer and degenerative diseases, including its lead product CTM-N2D in Phase I clinical trials and collaborations with Sengkang General Hospital and SunAct Cancer Institute, its business model faces an inherent conflict with "Kind to Animals" due to the necessary reliance on animal testing in pre-clinical drug development. The actual impact on public health remains potential at this early stage.

Value Scores

Better Health for All0
-100100
Fair Money & Economic Opportunity0
-100100
Fair Pay & Worker Respect0
-100100
Fair Trade & Ethical Sourcing0
-100100
Honest & Fair Business0
-100100
Kind to Animals0
-100100
No War, No Weapons0
-100100
Planet-Friendly Business0
-100100
Respect for Cultures & Communities0
-100100
Safe & Smart Tech0
-100100
Zero Waste & Sustainable Products0
-100100

Better Health for All

0

No evidence available to assess CytoMed Therapeutics Limited on Better Health for All.

Fair Money & Economic Opportunity

0

CytoMed Therapeutics Limited is a biotechnology company focused on the research and development of immunotherapies for cancer. Its core business does not involve lending, insuring, moving, or storing money, nor does it offer financial products or services to consumers. Therefore, all KPIs related to financial services, such as customer segments for lending, APRs, fee structures, financial inclusion programs, customer finance data, fair lending compliance, wealth building outcomes, community finance reinvestment, financial literacy, debt burden, banking access points, or financial product simplicity, are not applicable to the company's operations. The evidence provided discusses the cost of medical treatments, subsidies for these treatments, and locations of clinical trials, which are outside the scope of 'Fair Money & Economic Opportunity' as defined for financial institutions.

1

Fair Pay & Worker Respect

0

No specific, quantitative data points were provided across the articles to assess GDTC.US against the KPIs for Fair Pay & Worker Respect. While outlines a Code of Business Conduct and Ethics emphasizing fair dealing and compliance with laws, it does not provide evidence of outcomes such as living wage coverage, pay ratios, collective bargaining, safety incident rates, pay equity, worker engagement, turnover rates, labor violation incidents, insecure contract share, or health insurance coverage.

1
mentions employee benefits expenses of US$453,321 in 2024, an increase driven by headcount and salary rates, but does not specify the percentage of the workforce covered by health insurance or other specific benefits.
2

Fair Trade & Ethical Sourcing

0

No relevant data was found in the provided articles to assess CytoMed Therapeutics Limited against the 'Fair Trade & Ethical Sourcing' ethical value. The articles either explicitly stated no relevant information or indicated that the requested pages were not found, preventing any scoring for the defined KPIs.

Honest & Fair Business

0

No evidence available to assess CytoMed Therapeutics Limited on Honest & Fair Business.

Kind to Animals

0

No information relevant to the 'Kind to Animals' value or its associated Key Performance Indicators (KPIs) was found in the provided articles. The articles did not contain any specific data points regarding cruelty-free certifications, alternative testing methods, humane certifications for operations, wildlife conservation impact, ethical input substitution, supplier audits for welfare, cage-free sourcing, animal testing policy or volume, innovation investment in animal-free technologies, animal agriculture ethics, animal-free R&D collaboration, or public policy engagement on animal welfare.

1

No War, No Weapons

0

CytoMed Therapeutics Limited is a biotechnology company focused on developing cell-based immunotherapies for cancer and degenerative diseases.

1
Its core business activities, including R&D, clinical trials, and private blood banking services, are entirely unrelated to arms manufacturing, defense contracts, dual-use technologies, or any conflict-related activities.
2
Therefore, all KPIs under the 'No War, No Weapons' value are not applicable to the company's operations.
3

Planet-Friendly Business

0

No relevant data was found in the provided articles to assess GDTC.US against the 'Planet-Friendly Business' ethical value. The articles focus on general biopharmaceutical industry news, FDA actions, clinical trials, mergers, acquisitions, and research overhead cuts, without providing any specific information on GDTC.US's environmental performance, policies, or initiatives.

1

Respect for Cultures & Communities

0

No specific, concrete data points were found in the provided articles to assess CytoMed Therapeutics Limited against any of the KPIs for the 'Respect for Cultures & Communities' value. The articles primarily focus on business and research collaborations with medical institutions and clinical trial details, without addressing community engagement, cultural impact, or related metrics as defined by the rubric.

1

Safe & Smart Tech

0

CytoMed Therapeutics (Malaysia) Sdn Bhd's Personal Data Protection Notice, effective December 21, 2022, outlines compliance with the Personal Data Protection Act 2010 (Malaysia).

1
The company uses encryption, specifically TLS, for online transactions and secure cloud storage.
2
Users are granted rights to access, correct, and withdraw consent for their personal data.
3

Zero Waste & Sustainable Products

0

No specific, concrete evidence regarding GDTC.US's performance on waste diversion, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero waste certification, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education was found in the provided articles. The articles either discussed unrelated topics or were not found.

Own CytoMed Therapeutics Limited?

Upload your portfolio and see how all your holdings score across 11 ethical dimensions.

Audit My Portfolio

AI-generated analysis based on publicly available data. Not financial advice. Ratings are expressions of opinion derived from automated models and may contain inaccuracies. See our Risk Disclosure for full details.